2024-05-06 14:15:02 ET
Historical Analyst Recommendations
Latest 10 recommendationsFull story available on KlickAnalytics.com
2024-05-06 14:15:02 ET
Market Wire News is a media platform, the information on this page was provided by KlickAnalytics via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), will present up...
- Transformative Development and Co-Commercialization Collaboration with Chiesi - - Ongoing PROSERA Phase 3 Study in PAH Expected to Readout in Q4 2025 - - Registrational Phase 3 in PH-ILD Expected to Commence in Mid-2025 - - TORREY Phase 2 PAH Results Published in Lancet ...
Gossamer Bio Inc (NASDAQ:GOSS) and Italy-based Chiesi Farmaceutici S.p.A, have entered a global collaboration and license agreement ...